GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (LTS:0OB3) » Definitions » Cyclically Adjusted Revenue per Share

Valneva SE (LTS:0OB3) Cyclically Adjusted Revenue per Share : €1.81 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Valneva SE Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Valneva SE's adjusted revenue per share for the three months ended in Mar. 2024 was €0.228. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €1.81 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Valneva SE's average Cyclically Adjusted Revenue Growth Rate was 3.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 17.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Valneva SE was 17.60% per year. The lowest was 16.20% per year. And the median was 16.90% per year.

As of today (2024-06-06), Valneva SE's current stock price is €3.854. Valneva SE's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €1.81. Valneva SE's Cyclically Adjusted PS Ratio of today is 2.13.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Valneva SE was 23.42. The lowest was 1.76. And the median was 4.10.


Valneva SE Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Valneva SE's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Cyclically Adjusted Revenue per Share Chart

Valneva SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.10 1.10 1.37 1.73 1.81

Valneva SE Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.75 1.77 1.78 1.81 1.81

Competitive Comparison of Valneva SE's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Valneva SE's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valneva SE's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Valneva SE's Cyclically Adjusted PS Ratio falls into.



Valneva SE Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Valneva SE's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.228/119.4700*119.4700
=0.228

Current CPI (Mar. 2024) = 119.4700.

Valneva SE Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.143 100.180 0.171
201409 0.216 99.920 0.258
201412 0.198 99.860 0.237
201503 0.266 100.170 0.317
201506 0.252 100.440 0.300
201509 0.274 99.950 0.328
201512 0.280 100.040 0.334
201603 0.330 100.020 0.394
201606 0.346 100.630 0.411
201609 0.236 100.340 0.281
201612 0.353 100.650 0.419
201703 0.343 101.170 0.405
201706 0.282 101.320 0.333
201709 0.261 101.330 0.308
201712 0.383 101.850 0.449
201803 0.440 102.750 0.512
201806 0.325 103.370 0.376
201809 0.253 103.560 0.292
201812 0.421 103.470 0.486
201903 0.359 103.890 0.413
201906 0.312 104.580 0.356
201909 0.323 104.500 0.369
201912 0.363 104.980 0.413
202003 0.383 104.590 0.437
202006 0.140 104.790 0.160
202009 0.124 104.550 0.142
202012 0.559 104.960 0.636
202103 0.251 105.750 0.284
202106 0.249 106.340 0.280
202109 0.215 106.810 0.240
202112 2.882 107.850 3.193
202203 0.201 110.490 0.217
202206 0.657 112.550 0.697
202209 1.478 112.740 1.566
202212 0.802 114.160 0.839
202303 0.240 116.790 0.246
202306 0.285 117.650 0.289
202309 0.281 118.260 0.284
202312 0.302 118.390 0.305
202403 0.228 119.470 0.228

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Valneva SE  (LTS:0OB3) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Valneva SE's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.854/1.81
=2.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Valneva SE was 23.42. The lowest was 1.76. And the median was 4.10.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Valneva SE Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Valneva SE's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Valneva SE (LTS:0OB3) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (LTS:0OB3) » Definitions » Cyclically Adjusted Revenue per Share
Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.

Valneva SE (LTS:0OB3) Headlines

No Headlines